Fewer patients will be receiving the erythropoiesis-stimulating agents Eprex (epoetin) and Aranesp (darbepoetin)
June 2007
Fewer patients will be receiving the erythropoiesis-stimulating agents Eprex (epoetin) and Aranesp (darbepoetin).
Chronic kidney disease. Erythropoiesis-stimulating agents (ESAs) are associated with an increase in death and cardiovascular events when used to boost hemoglobin above 120 g/L.
These drugs can increase thrombosis risk.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive